At UT MD Anderson, we are committed to advancing the quality of and access to cancer care across the globe. Supported by unparalleled resources and a culture of collaborative science, our researchers pursue bold hypotheses and test innovative ideas that drive breakthroughs and transform results to meet our goal of eliminating the global cancer burden.
At the European Society for Medical Oncology (ESMO) Congress, UT MD Anderson experts showcase the latest advances in cancer care and lead critical conversations on translating these discoveries into clinical practice to benefit patients worldwide.
Explore our presentation highlights and learn more about our global reach below.
Featured Articles
Meet the Experts
Visit UT MD Anderson at Booth 8006 (in Hall 8) to network with us, to ask a question, to learn about training and career opportunities and to continue the conversation on key presentations with our experts.
Exhibit Hall Hours
- Friday, Oct. 23: 10:00 a.m.¨C6:30 p.m.
- Saturday, Oct. 24: 10:00 a.m.¨C6:30 p.m.
- Sunday, Oct. 25: 10:00 a.m.¨C6:30 p.m.
- Monday, Oct. 26: 10:00 a.m.¨C6:30 p.m.
Featured Videos
Featured Abstracts
ESMO 2026: Immunotherapy combination extends survival in advanced endometrial cancer
Patients receiving durvalumab plus olaparib lived almost one year longer than patients treated with chemotherapy alone?
Study results were especially encouraging for patients with tumors with mismatch repair proficiency
Updated Phase 3 findings provide the first overall survival analysis demonstrating durable benefits beyond delaying disease progression
ABSTRACT:
An immunotherapy-based regimen combining durvalumab and the PARP inhibitor, olaparib, demonstrated encouraging long-term survival outcomes for patients with advanced or recurrent endometrial cancer, according to new trial results presented by researchers from Â鶹ӳ» MD Anderson Cancer Center.?
In the global Phase 3 DUO-E trial, treatment with durvalumab plus chemotherapy followed by durvalumab and olaparib achieved a median overall survival of 51.1 months, which was 11.5 months longer than with chemotherapy alone. The findings were presented today at the by principal investigator , professor of Gynecologic Oncology and Reproductive Medicine.
"These results demonstrate that combining immunotherapy with a PARP inhibitor can deliver durable survival benefits for patients with advanced or recurrent endometrial cancer," Westin said. "The findings are particularly noteworthy for patients with pMMR tumors, who represent the majority of cases and have traditionally had fewer effective treatment options."??
What are the other key findings of the DUO-E trial??
The trial randomized 718 patients with advanced or recurrent endometrial cancer to receive one of three treatment regimens. One group received chemotherapy alone followed by placebo in the maintenance phase. The other two groups received chemotherapy with durvalumab followed by durvalumab with or without olaparib in the maintenance phase.
The study previously met its primary progression-free survival endpoints. The current analysis evaluated overall survival and long-term safety profiles. No new safety concerns were observed, and side effects remained consistent with previous findings.
Researchers also reported durable benefits across several secondary endpoints. Patients receiving durvalumab followed by durvalumab and olaparib experienced longer periods before requiring subsequent therapy and remained on treatment longer than those receiving chemotherapy alone. At 36 months, 63.4% of patients in the durvalumab-plus-olaparib arm were alive, compared with 52% of patients in the chemotherapy arm.?
Researchers also observed additional benefits among patients with mismatch repair proficient (pMMR) tumors, who represent the majority of endometrial cancer cases and have historically had fewer effective treatment options. The addition of olaparib, a PARP inhibitor that interferes with cancer cells' DNA repair mechanisms, may help explain the broader benefit seen across patient subgroups.
Why are these findings important?
Endometrial cancer is the most common gynecologic cancer in the U.S. and approximately 66,000 women are diagnosed each year.?
Women with advanced or recurrent endometrial cancer have limited treatment options and historically face poor outcomes once the disease spreads or returns after initial treatment. The results suggest that combining immunotherapy with targeted maintenance therapy may help patients live longer while also delaying the need for additional treatment.?
The results support an approach that combines immunotherapy and targeted therapy earlier in the treatment journey, before the disease progresses.
Researchers will continue the DUO-E study to look into a final anlysis of overall survival. ?
+++
The study was funded by AstraZeneca. A full list of collaborating authors and their disclosures can be found with the .
ESMO 2026: New targeted therapy improved survival for patients with KRAS-mutated lung cancer
Phase 3 trial finds that next-generation KRAS G12C inhibitor divarasib significantly reduced risk of cancer progressing and death
Patients receiving divarasib lived a median of approximately 18 months?
Fewer severe treatment-related side effects were reported with divarasib
ABSTRACT:
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from Â鶹ӳ» MD Anderson Cancer Center.?
Results from the global Phase 3 K???rascendo 1? study were published today in and presented at the 2026. The study was led by principal investigator?, professor of Thoracic/Head and Neck Medical Oncology.?
On the trial, researchers compared divarasib with two currently approved KRAS G12C inhibitors, sotorasib or adagrasib, in NSCLC patients whose cancer had progressed after prior treatment. Treatment with divarasib reduced the risk of disease progression by 42% and the risk of death by 44%. Median overall survival improved with divarasib to 17.7 months versus 12 months with sotorasib/adagrasib.?
¡°For patients with KRAS G12C-mutant lung cancer, extending survival while delaying cancer progression are the outcomes that matter most,¡± Skoulidis said. ¡°Divarasib significantly improved both measures compared with currently available KRAS inhibitors. These results establish divarasib as a new standard of care and offer hope for patients whose treatment options have been limited after their cancer progresses."
What is KRAS-mutant lung cancer??
KRAS is one of the most commonly altered genes in NSCLC, and these mutations allow cancer cells to grow uncontrollably. Approximately 14% of patients with NSCLC have a specific type of mutation, known as KRAS G12C.?
While KRAS was once thought to be undruggable, in recent years, KRAS G12C inhibitors (including sotorasib and adagrasib) became the first approved therapies designed to specifically target the mutation.?
Why is the K?rascendo 1? study important for patients with KRAS-mutant lung cancers?
Divarasib is a next-generation oral targeted therapy designed to block KRAS G12C more effectively than the therapies that are currently approved. The treatment works by locking the abnormal KRAS protein in an inactive state, essentially switching off a key signal that cancer cells depend on to grow and survive.?
Krascendo 1 is the first Phase 3 trial to directly compare a next-generation KRAS inhibitor with approved KRAS-targeted treatments, providing important evidence about whether a newer generation of these medicines can help patients live longer.?
What are the other key findings of the Krascendo 1 study??
The trial enrolled 338 patients with previously treated advanced or metastatic KRAS G12C-mutant NSCLC at 151 centers across 26 countries. Participants were randomly assigned to receive either divarasib, sotorasib or adagrasib.
After a median follow-up of 14.3 months, patients treated with divarasib experienced a median progression-free survival of 9.8 months compared with 5.7 months for those receiving standard KRAS inhibitors. At one year, 44% of patients receiving divarasib remained free from disease progression or death versus 24% of those in the control group.?
On top of the improved overall survival?, ?patients were nearly twice as likely to respond to treatment with divarasib versus the control treatment???. The overall response rate was 58.4% compared with 32.3% for standard therapy, and responses lasted longer, with a median duration of response of 11.9 months versus 6.9 months.
Importantly, improved efficacy did not come at the cost of increased toxicity. Divarasib was better tolerated, with severe treatment-related side effects occurring in 25% of patients compared with 35% of those receiving current KRAS-targeted therapies, despite receiving divarasib treatment twice as long.
Limitations of the study include its open-label design and the relatively small number of patients in the control group who received adagrasib. In addition, patients with untreated brain metastases were not eligible for enrollment.
***
This study was sponsored by F. Hoffmann-La Roche Ltd. (Roche) and Genentech, Inc. A full list of authors, disclosures and funding information can be found with the publication in .
Our research by the numbers
$1.3B
invested in research
1,579
clinical trials in FY25
140
patents awarded to UT MD Anderson in FY25
Our Global Reach
UT MD Anderson has one singular mission: to end cancer. But we can¡¯t do it alone. A future without cancer requires that we work together ¡ª locally, nationally and globally ¡ª to improve care for cancer patients, fuel groundbreaking research, and implement evidence-based prevention and screening approaches. Learn about our international collaborations aimed at advancing global cancer care.
UT MD Anderson joins global consortium committed to eliminating cervical cancer
The collaboration agreement with the Elimination Partnership in Cervical Cancer (EPICC) expands UT MD Anderson¡¯s global oncology efforts, further strengthening its commitment to advancing cancer prevention and control in medically underserved regions. Read more about the collaboration
A few of our collaborators
-
World Health Organization (WHO)
UT MD Anderson and WHO establish new international collaboration to reduce women¡¯s cancers
-
Pan American Health Organization (PAHO)
UT MD Anderson and Pan American Health Organization join forces to support cancer prevention and control in the Americas
-
International Atomic Energy Agency (IAEA)
UT MD Anderson designated IAEA Collaborating Centre to focus on improving radiation, radiology and nuclear medicine worldwide
-
Zambia Ministry of Health
UT MD Anderson expands global oncology efforts through new agreement with Zambia Ministry of Health
-
Ministry of Health in Mozambique
UT MD Anderson announces new initiatives in Mozambique and Brazil to advance cancer prevention, treatment, research and education efforts
-
Ministry of Health in Indonesia
UT MD Anderson announces new collaboration in Indonesia to reduce global cancer burden
Education and Training at UT MD Anderson
UT MD Anderson academic programs are competitive and comprehensive. We offer educational opportunities from undergraduate degrees to graduate medical education opportunities.
Institutes at UT MD Anderson
United by a shared mission to end cancer, UT MD Anderson clinicians and scientists work seamlessly together to advance groundbreaking research that can transform the field of hematology. Leveraging our unique research ecosystem, including three leading institutes, we are pioneering new prevention, diagnostic and treatment approaches to address the most pressing needs for patients with cancer.
The James P. Allison Institute is dedicated to advancing exceptional discovery, translational and clinical research to integrate immunobiology across disciplines and unlock the full potential of science and medicine for human health. The institute builds upon the legacy of its namesake, James P. Allison, Ph.D., who was awarded the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer.
Building upon unparalleled expertise, the Institute for Cell Therapy Discovery & Innovation is leading the world in developing and advancing impactful cell therapies for patients in need. By uniting the top minds in the field to lead exceptional fundamental, translational and clinical research, we're focused on creating breakthrough off-the-shelf therapies that can be readily adapted for both hematologic and solid tumors as well as devastating auto-immune conditions, infections and other diseases.
Learn more about the Institute for Cell Therapy Discovery & Innovation
The Institute for Data Science in Oncology (IDSO) integrates the tremendous power of meaningful data extraction and interpretation with UT MD Anderson¡¯s unparalleled scientific and clinical expertise to transform research and care to impact patients.